| Literature DB >> 30485814 |
Iréna Lassot1, Stéphan Mora2, Suzanne Lesage3, Barbara A Zieba2, Emmanuelle Coque2, Christel Condroyer3, Jozef Piotr Bossowski2, Barbara Mojsa2, Cecilia Marelli2, Caroline Soulet2, Christelle Tesson3, Iria Carballo-Carbajal4, Ariadna Laguna4, Graziella Mangone3, Miquel Vila5, Alexis Brice3, Solange Desagher2.
Abstract
Although accumulating data indicate that increased α-synuclein expression is crucial for Parkinson disease (PD), mechanisms regulating the transcription of its gene, SNCA, are largely unknown. Here, we describe a pathway regulating α-synuclein expression. Our data show that ZSCAN21 stimulates SNCA transcription in neuronal cells and that TRIM41 is an E3 ubiquitin ligase for ZSCAN21. In contrast, TRIM17 decreases the TRIM41-mediated degradation of ZSCAN21. Silencing of ZSCAN21 and TRIM17 consistently reduces SNCA expression, whereas TRIM41 knockdown increases it. The mRNA levels of TRIM17, ZSCAN21, and SNCA are simultaneously increased in the midbrains of mice following MPTP treatment. In addition, rare genetic variants in ZSCAN21, TRIM17, and TRIM41 genes occur in patients with familial forms of PD. Expression of variants in ZSCAN21 and TRIM41 genes results in the stabilization of the ZSCAN21 protein. Our data thus suggest that deregulation of the TRIM17/TRIM41/ZSCAN21 pathway may be involved in the pathogenesis of PD.Entities:
Keywords: E3 ubiquitin-ligases; Parkinson disease; TRIM17; TRIM41; ZSCAN21; transcriptional regulation; ubiquitin-proteasome system; α-synuclein/SNCA
Year: 2018 PMID: 30485814 DOI: 10.1016/j.celrep.2018.11.002
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423